West Pharmaceutical Services (NYSE:WST) Updates Q2 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its second quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.050-2.120 for the period, compared to the consensus earnings per share estimate of 2.000. The company issued revenue guidance of $830.0 million-$850.0 million, compared to the consensus revenue estimate of $818.7 million. West Pharmaceutical Services also updated its FY 2026 guidance to 8.400-8.750 EPS.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on WST. UBS Group reiterated a “buy” rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Evercore decreased their price target on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a research note on Tuesday, February 3rd. Barclays upped their price target on West Pharmaceutical Services from $265.00 to $275.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $315.67.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $274.59 on Thursday. The business has a 50 day moving average price of $250.67 and a 200 day moving average price of $261.77. West Pharmaceutical Services has a twelve month low of $199.89 and a twelve month high of $322.34. The company has a market cap of $19.79 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 2.92 and a beta of 1.15. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm had revenue of $805.00 million during the quarter, compared to the consensus estimate of $795.70 million. During the same quarter in the prior year, the company earned $1.82 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Research analysts predict that West Pharmaceutical Services will post 7.91 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.96%.

West Pharmaceutical Services announced that its board has authorized a stock buyback plan on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Institutional Trading of West Pharmaceutical Services

A number of hedge funds have recently modified their holdings of the company. Aptus Capital Advisors LLC lifted its position in shares of West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 47 shares during the period. IFM Investors Pty Ltd lifted its position in shares of West Pharmaceutical Services by 0.4% in the 4th quarter. IFM Investors Pty Ltd now owns 13,730 shares of the medical instruments supplier’s stock worth $3,778,000 after acquiring an additional 49 shares during the period. Benjamin Edwards Inc. lifted its position in shares of West Pharmaceutical Services by 1.7% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock worth $661,000 after acquiring an additional 50 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of West Pharmaceutical Services by 4.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,207 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 53 shares during the period. Finally, Caerus Investment Advisors LLC lifted its position in shares of West Pharmaceutical Services by 6.2% in the 4th quarter. Caerus Investment Advisors LLC now owns 1,035 shares of the medical instruments supplier’s stock worth $285,000 after acquiring an additional 60 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.